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Abstract
Background: Varicella (chickenpox) is the primary disease caused by varicella-zoster virus. It is
extremely contagious and is frequent in children. Indeed, in the absence of vaccination, a high
proportion of the population is liable to contract it. Herpes zoster -more frequent among adults-
is caused by reactivation of the latent virus. The objective of this study is to describe the status of
and time trend for varicella and herpes zoster in the Madrid Autonomous Region prior to the
introduction of the vaccine to the general population.
Methods: Data source: individualised varicella and herpes zoster case records kept by the Madrid
Autonomous Region Sentinel General Practitioner Network for the period 1997–2004.
Cumulative incidences, crude and standardised incidence rates, and age-specific rates of varicella
and herpes zoster were calculated for each year. Kendall's Tau-b correlation coefficient was
calculated to evaluate whether incidence displayed a time trend. Spectral density in the time series
of weekly incidences was estimated using a periodogram.
Results: Standardised annual varicella incidence rates ranged from 742.5 (95% CI: 687.2 – 797.7)
to 1239.6 (95% CI: 1164.5 – 1313.4) cases per 100 000 person-years. Most cases affected children,
though complications were more frequent in adults. Varicella incidence displayed an annual
periodicity but no trend over time. Most herpes zoster cases occurred at advanced ages, with
incidence registering a rising annual trend but no seasonality factor.
Conclusion: In the absence of vaccination, no significant changes in varicella incidence were in
evidence recent years, though these were observed in the incidence of herpes zoster. Sentinel
general practitioner networks are a valid instrument for surveillance of diseases such as varicella.
Further varicella vaccination-coverage and vaccine-efficacy studies are called for.
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Background
Varicella (chickenpox) is the primary disease caused by
the varicella-zoster virus. It mainly affects children and, in
most cases, its clinical features include mild vesicular
exanthema. Although less frequent among adults, the dis-
ease can nevertheless be more severe, leading to a greater
number of complications which may even prove life-
threatening[1]. Due to its extreme contagiousness, in the
absence of vaccination most people have suffered from
the disease by the time they reach adulthood.
Herpes zoster is a secondary infection caused by reactiva-
tion of the latent virus, and principally affects adults[1,2].
It is less frequent than varicella, and the risk of suffering
herpes zoster over the course of a lifetime has been esti-
mated between 20 at 30%[1,3].
The introduction of universal varicella vaccination in chil-
dren has been controversial, owing to its possible effects
on the disease itself and on herpes zoster[4]. Initially the
vaccine was exclusively used on immunodepressed
patients, but subsequently its general use was authorised
in a number of countries, including Japan, South Korea
(1988)[5], United States[6], Sweden and Germany
(1995). In Spain it was first introduced in 1997 for high-
risk patients, and in 2005 it was included in the vaccina-
tion schedule for administration to adolescents who had
not suffered the illness, whereas the Spanish Paediatric
Association as been recommending vaccination in chil-
dren as from the age of 12 months since 1999[7].
Recently, the Madrid Autonomous Region (MAR) has
included universal varicella vaccination in its systematic
vaccination schedule for children aged 15 months[8].
According to a series of studies, the varicella vaccine now
in use in various countries is effective[9,10]. As regards the
immunity conferred, some studies indicate that it is
high[5] but this is not yet clear[10] and it would seem that
at least two doses of vaccine are needed[11,12].
A vaccine against herpes zoster and post-herpetic neural-
gia is currently being developed, and it is not well known
about how this may influence the possible effect of vari-
cella immunisation on herpes zoster and, as a result, on
the indications and effectiveness of the herpes zoster vac-
cine[13,14].
Sentinel networks are an increasingly useful tool in epide-
miological surveillance and research. The MAR Sentinel
General Practitioner Network (SGPN) came into opera-
tion in 1991, and the reporters are volunteer physicians.
This study sought to describe the status of and evolution
for varicella and herpes zoster in the MAR, based on case
reports of the SGPN, from 1997, the year in which these
diseases first came under surveillance, until 2004, prior to
the introduction of the varicella vaccine into the general
population.
Methods
The Madrid Region Sentinel General Practitioner Network
is made up of general practitioners and primary care pae-
diatricians who voluntarily submit weekly reports of cases
of varicella and herpes zoster, as well as other diseases.
The population attended by these physicians is represent-
ative, in terms of age and gender, and accounts for approx-
imately 2% of the total population of the MAR.
Case definitions
A case of varicella was defined as an acute disease with
moderate fever (< 38.5°C) and vesicular exanthema,
which evolves in the form of outbreaks, and gives rise to
lesions that swiftly develop from superficial papules into
vesicles, and occasionally into scabs. A case of herpes
zoster was defined as a vesicular rash, generally unilateral,
with dermatomeric distribution.
Apart from age and sex, data recorded in varicella cases
included previous exposure to other cases of varicella or
herpes zoster, place of exposure (if known), as well as
complications suffered (bacterial infection, pneumonia,
and neurological and other complications).
The following were calculated for both varicella and her-
pes zoster: cumulative weekly incidences for the overall
study period; and, crude and standardised incidence rates
for the standard European population and age-specific
rates for each year.
Kendall's Tau-b correlation coefficient was calculated to
evaluate whether annual varicella and herpes zoster inci-
dence described a trend over time. Similarly, spectral den-
sity in the time series of weekly incidences was estimated,
using a periodogram and Tukey-Hamming smoothing.
SPSS® 12.0 statistical package was used.
This study complies with all current international ethic
norms.
Results
In the period from 1997 to 2004, a total of 9856 cases of
varicella and 1798 cases of herpes zoster were reported to
the Madrid Region SGPN.
For varicella, the standardised annual incidence rates
ranged from 742.5 (95% CI: 687.2 – 797.7) to 1239.6
(95% CI: 1164.5 – 1313.4) cases per 100000 person-years
(Figure 1). Of this total, 51.4% of cases occurred among
males and 48.6% among females.
Close on 60% of cases occurred among children under 5
years of age, and almost 90% among children under 10
years of age (Figure 2). 81% of cases with known exposure
were exposed to another varicella case, 1.4% had been in
contact with a herpes zoster case, and 17.7% belonged toBMC Infectious Diseases 2007, 7:59 http://www.biomedcentral.com/1471-2334/7/59
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outbreaks. The main places of exposure were nursery and
school (74.3%), and home (25.0%).
Time-trend analysis yielded a Kendall Tau-b correlation
coefficient for incidence and time of 0.43 (p = 0.138). The
distribution of weekly varicella incidences depicted in Fig-
ure 3 suggests an annual periodicity. This same periodicity
is observable in the varicella time series periodogram (Fig-
ure 4), which shows a high spectral density in the 52-week
period.
Among the 9856 cases, 364 complications (3.7%) were
reported. The highest percentages of complications were
registered in respect of the oldest age groups (Table 1),
and the greatest number consisted of cutaneous infections
(68.6%).
The standardised annual herpes zoster incidence rates
ranged from 249.9 (95% CI: 217.9 – 282.0) to 359.4
(95% CI: 322.3 – 396.6) cases per 100000 person-years
(Figure 1). In all, 59.2% of cases occurred among females,
and 40.8% among males. The highest incidences were reg-
istered in respect of the oldest age groups (Figure 5). For
the oldest age groups a rising trend was observed in both
overall and specific incidences, a finding confirmed by a
Kendall Tau-b correlation coefficient of 0.64 (p = 0.026).
Unlike varicella, there was no evidence of seasonality in
the herpes zoster time series.
For varicella, 0.2 % of cases carried no record of patient's
gender, and 5.2% had missing values of age. For herpes
zoster 0.1% of missing values were founded in patient's
gender.
Discussion
There was no significant shift in trend in annual incidence
of varicella in Madrid from 1997 to 2004, despite the fact
that the annual rates display rises and falls. As this pattern
was almost identically reproduced in children aged under
5 years, among whom incidence is highest, the analysis
was not repeated for that age group. An important season-
ality factor was in evidence, with peaks in incidence from
May to July, and lows towards October. Distribution by
gender showed no differences. These results are similar to
others obtained in other countries [15-17].
Annual cumulative weekly incidences of varicella per 100,000  population. Madrid Region Sentinel General Practitioner  Network: 1997–2004 Figure 3
Annual cumulative weekly incidences of varicella per 
100,000 population. Madrid Region Sentinel General 
Practitioner Network: 1997–2004. Weekly cumulative 
incidence has been expressed as cases per 100,000 persons.
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Age-specific varicella incidence rates. Madrid Region Sentinel  General Practitioner Network: 1997–2004 Figure 2
Age-specific varicella incidence rates. Madrid Region 
Sentinel General Practitioner Network: 1997–2004. 
Age-specific varicella incidence rates are expressed as cases 
per 100,000 person-years. The ages over 15 years have been 
joined as the incidence is very low.
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Annual varicella and herpes zoster incidence in the Madrid  Region. Madrid Sentinel General Practitioner Network Figure 1
Annual varicella and herpes zoster incidence in the 
Madrid Region. Madrid Sentinel General Practitioner 
Network. Annual incidence rates of varicella and herpes 
zoster are presented. Rates are expressed in cases per 
100,000 person-years. In the left axis are presented rates for 
varicella, and in the right axis, the rates for herpes zoster.
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Few complications were observed, and these mostly con-
sisted of bacterial skin overinfections. Note should how-
ever be taken of the fact that the most severe
complications were least frequent. Hence, the SGPN may
conceivably not detect all complications because it works
with a representative sample that covers approximately
2% of the population of Madrid. Moreover, most of com-
plications of varicella receive hospital attention and are
not collected by the SGPN[18].
In contrast to varicella, herpes zoster registered a sustained
and significant rise in annual incidence, particularly
among the oldest age groups, though there was no evi-
dence of seasonality[2]. Again unlike varicella, and as
described elsewhere, there was a higher percentage of
cases among females than males[2,19].
The universal vaccination is currently a widely debate sub-
ject, with objections[13,20,21] and defenders[22,23],
including clinical and cost-effectiveness aspects [24-27].
Starting from data as presented in this work, further stud-
ies are called for to evaluate the vaccine, its effectiveness
and the duration of immunity.
The number of Sentinel Networks has grown worldwide
since the 1960's and they are used in fields as diverse as
communicable [28-30] and non-communicable disease
surveillance[31,32]. In Madrid, SGPN has demonstrated
to be an efficient and useful system for the epidemiologic
Age-specific herpes zoster incidence rates. Madrid Region  Sentinel General Practitioner Network: 1997–2004 Figure 5
Age-specific herpes zoster incidence rates. Madrid 
Region Sentinel General Practitioner Network: 
1997–2004. Age-specific herpes zoster incidence rates are 
expressed as cases per 100,000 person-years.
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Periodogram depicting the time series of cumulative varicella  incidence. Madrid Region Sentinel General Practitioner Net- work: 1997–2004 Figure 4
Periodogram depicting the time series of cumulative 
varicella incidence. Madrid Region Sentinel General 
Practitioner Network: 1997–2004. The figure shows the 
periodicity of peaks in varicella incidence using a week as 
time unit. The peaks in periodogram reveal when the pattern 
repeats.
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Table 1: Varicella case complications detected by the Madrid Region Sentinel General Practitioner Network from 1997 to 2004, by age 
group.
Age (years)
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35 and over
C u t a n e o u s  o v e r i n f e c t i o n 1 2 4 5 9 1 2 2578 1 0
P n e u m o n i a 1 7 5 11102 0
Neurological complications 1 1 00000 0
Otitis media 1 9 4 20000 0
Conjunctivitis and other ophthalmological complications 14 9 30000 0
O t h e r 2 0 3 00000 1
Total 195 81 18 3 6 7 10 11
Percentage of complicated cases of varicella 3.5 3.0 3.1 3.6 5.9 7.4 10.0 7.7BMC Infectious Diseases 2007, 7:59 http://www.biomedcentral.com/1471-2334/7/59
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surveillance of several diseases, and especially for varicella
and herpes zoster.
Conclusion
In recent years, the time trend in respect of varicella inci-
dence among subjects who were not covered by universal
varicella vaccination has remained stable. Although the
percentage of complications is not high, these are never-
theless more frequent among adults. Incidence of herpes
zoster maintained a rising trend over the study period.
Sentinel general practitioner networks are useful instru-
ments for epidemiological surveillance of diseases such as
varicella and herpes zoster.
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